Initial experience with hybrid argon plasma coagulation as a novel local treatment method for tracheobronchial mucoepidermoid carcinoma

• Verfasst von: Zheng, Xiaoxuan [VerfasserIn]
• Verfasst von: Herth, Felix [VerfasserIn]
• Verfasst von: Sun, Jiayuan [VerfasserIn]
• Titel: Initial experience with hybrid argon plasma coagulation as a novel local treatment method for tracheobronchial mucoepidermoid carcinoma
• Verf.angabe: Xiaoxuan Zheng, Felix J.F. Herth, Jiayuan Sun
• E-Jahr: 2019
• Jahr: September 27, 2019
• Umfang: 6 S.
• Teil: volume:98
• Teil: year:2019
• Teil: number:5
• Teil: pages:461-466
• Teil: extent:6
• Fussnoten: Gesehen am 30.01.2020
• Titel Quelle: Enthalten in: Respiration
• Ort Quelle: Basel : Karger, 1944
• Jahr Quelle: 2019
• Band/Heft Quelle: 98(2019), 5, Seite 461-466
• ISSN Quelle: 1423-0356
• DOI: doi:10.1159/000501239
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1688909885

Abstract

Tracheobronchial mucoepidermoid carcinoma (MEC) is a type of salivary gland tumor. Surgical resection is the main treatment for MEC, but it is associated with risks. Hybrid argon plasma coagulation (HybridAPC®) is an innovative technique combining APC with a water cushion function which can be used for the treatment of MEC. We aimed to evaluate the efficacy and safety of HybridAPC for MEC in 2 patients diagnosed with MEC based on histological examination of biopsies. Full preoperative assessments were done by white-light bronchoscopy, autofluorescence imaging, narrow-band imaging, and radial probe endobronchial ultrasound. HybridAPC was administered after these evaluations. Both patients were followed up for more than 3 months. HybridAPC ablation was completed successfully, with no complications. HybridAPC thus appears to be a safe and efficient treatment for MEC.